Concepción Boqué

3.7k total citations · 2 hit papers
23 papers, 2.3k citations indexed

About

Concepción Boqué is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Concepción Boqué has authored 23 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 16 papers in Hematology and 5 papers in Rheumatology. Recurrent topics in Concepción Boqué's work include Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers). Concepción Boqué is often cited by papers focused on Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers). Concepción Boqué collaborates with scholars based in Spain, Italy and Germany. Concepción Boqué's co-authors include Andreas Hochhaus, Charles Chuah, Hagop M. Kantarjian, Michele Baccarani, Jörge E. Cortes, Neil P. Shah, Jiřı́ Mayer, Giuseppe Saglio, M. Brigid Bradley‐Garelik and George Manos and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Concepción Boqué

22 papers receiving 2.2k citations

Hit Papers

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phas... 2010 2026 2015 2020 2010 2016 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
    2010 1.1k citations Hagop M. Kantarjian, Neil P. Shah et al. New England Journal of Medicine profile →
  2. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
    2016 621 citations Jörge E. Cortes, Giuseppe Saglio et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Concepción Boqué Spain 9 2.0k 1.6k 1.0k 345 238 23 2.3k
Beatriz Moiraghi Argentina 13 1.8k 0.9× 1.5k 0.9× 1.0k 1.0× 309 0.9× 209 0.9× 42 2.1k
M. Brigid Bradley‐Garelik United States 15 2.2k 1.1× 1.9k 1.1× 1.2k 1.2× 351 1.0× 310 1.3× 28 2.5k
Philipp D. le Coutre Germany 23 2.3k 1.1× 1.9k 1.2× 1.2k 1.2× 449 1.3× 236 1.0× 72 2.5k
Valentín García‐Gutiérrez Spain 20 1.7k 0.8× 1.4k 0.9× 768 0.7× 390 1.1× 162 0.7× 104 2.0k
Albert Hoenekopp Switzerland 10 1.6k 0.8× 1.3k 0.8× 845 0.8× 253 0.7× 193 0.8× 21 1.8k
Athena Countouriotis United States 14 1.6k 0.8× 1.4k 0.9× 943 0.9× 323 0.9× 188 0.8× 21 1.9k
Franck E. Nicolini France 19 2.7k 1.3× 2.1k 1.3× 1.2k 1.2× 501 1.5× 256 1.1× 56 3.0k
Philippe Rousselot France 16 2.0k 1.0× 1.7k 1.0× 1.0k 1.0× 365 1.1× 209 0.9× 31 2.3k
P. Le Coutre Germany 5 1.3k 0.7× 1.1k 0.7× 673 0.7× 245 0.7× 158 0.7× 5 1.6k
Franck E. Nicolini France 19 1.5k 0.7× 1.2k 0.7× 697 0.7× 253 0.7× 209 0.9× 64 1.7k

Countries citing papers authored by Concepción Boqué

Since Specialization
Citations

This map shows the geographic impact of Concepción Boqué's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Concepción Boqué with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Concepción Boqué more than expected).

Fields of papers citing papers by Concepción Boqué

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Concepción Boqué. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Concepción Boqué. The network helps show where Concepción Boqué may publish in the future.

Co-authorship network of co-authors of Concepción Boqué

This figure shows the co-authorship network connecting the top 25 collaborators of Concepción Boqué. A scholar is included among the top collaborators of Concepción Boqué based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Concepción Boqué. Concepción Boqué is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Andriella, Antonio, et al.. (2024). Introducing Social Robots to Assess Frailty in Older Adults. DIGITAL.CSIC (Spanish National Research Council (CSIC)). 342–346. 5 indexed citations
2.
Andriella, Antonio, et al.. (2024). Exploring the Potential of a Robot-Assisted Frailty Assessment System for Elderly Care. DIGITAL.CSIC (Spanish National Research Council (CSIC)). 168–175.
3.
Hernández‐Boluda, Juan Carlos, María Teresa Gómez‐Casares, Rosa Ayala, et al.. (2023). Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial. Blood. 142(Supplement 1). 1795–1795. 1 indexed citations
4.
Boqué, Concepción, Silvia Sánchez‐Ramón, Raúl Córdoba, Carol Moreno, & Maria-Elena Cabezudo. (2023). Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations. Journal of Clinical Medicine. 12(19). 6356–6356. 1 indexed citations
5.
Estrada, Natàlia, Lurdes Zamora, Francisca Ferrer‐Marín, et al.. (2022). Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients. Journal of Clinical Medicine. 11(20). 6217–6217. 2 indexed citations
6.
Marcé, Sílvia, Blanca Xicoy, Olga García, et al.. (2021). Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. Journal of Clinical Medicine. 10(14). 3146–3146. 11 indexed citations
7.
Estrada, Natàlia, Blanca Xicoy, Fabian Beier, et al.. (2021). Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients. Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona). 1 indexed citations
8.
Boqué, Concepción, et al.. (2019). Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study. Journal of Geriatric Oncology. 11(1). 24–30. 5 indexed citations
9.
Boqué, Concepción, et al.. (2017). Healthcare Professionals’ Preferences for the Treatment Selection of Chronic Lymphocytic Leukemia (CLL): The Prelic Study. Value in Health. 20(9). A455–A455. 1 indexed citations
10.
Cortes, Jörge E., Giuseppe Saglio, Hagop M. Kantarjian, et al.. (2016). Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology. 34(20). 2333–2340. 621 indexed citations breakdown →
11.
Hernández‐Boluda, Juan Carlos, Fermín Sánchez‐Guijo, María Teresa Gómez‐Casares, et al.. (2016). Safety and efficacy of ponatinib in real world clinical practice. Results from the Spanish Compassionate Use Program. A GELMC study. RISalud Institutional Health Repository of Andalucía. 1 indexed citations
12.
García‐Gutiérrez, Valentín, Fermín Sánchez‐Guijo, Rosa Ayala, et al.. (2016). Safety and Efficacy of Dasatinib Treatment Change for Patients Previosly Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study. Blood. 128(22). 5450–5450. 1 indexed citations
13.
Sorigué, Marc, Josep‐María Ribera, Olga García, et al.. (2015). Highly variable mutational profile of ASXL1 in myelofibrosis. European Journal Of Haematology. 97(4). 331–335. 3 indexed citations
14.
Castillo, Inmaculada, et al.. (2014). [Effectiveness and safety of lenalidomide in myelofibrosis patients: a case series from the Spanish compassionate use program].. PubMed. 37(2). 135–42. 1 indexed citations
15.
Cortes, Jörge E., Giuseppe Saglio, Michele Baccarani, et al.. (2014). Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056). Blood. 124(21). 152–152. 59 indexed citations
16.
Besses, Carles, Concepción Boqué, Ana Kerguelen, et al.. (2014). Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain. Journal of Medical Economics. 17(6). 435–441. 6 indexed citations
17.
Jabbour, Elias, Hagop M. Kantarjian, Giuseppe Saglio, et al.. (2013). Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 123(4). 494–500. 301 indexed citations
18.
Kantarjian, Hagop M., Neil P. Shah, Andreas Hochhaus, et al.. (2010). Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine. 362(24). 2260–2270. 1103 indexed citations breakdown →
19.
20.
Román‐Gómez, José, Juan A. Castillejo, Antonio Jiménez, et al.. (2003). Cadherin-13, a Mediator of Calcium-Dependent Cell-Cell Adhesion, Is Silenced by Methylation in Chronic Myeloid Leukemia and Correlates With Pretreatment Risk Profile and Cytogenetic Response to Interferon Alfa. Journal of Clinical Oncology. 21(8). 1472–1479. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beatriz Moiraghi Breakdown of academic impact, for papers by M. Brigid Bradley‐Garelik Breakdown of academic impact, for papers by Philipp D. le Coutre Breakdown of academic impact, for papers by Valentín García‐Gutiérrez Breakdown of academic impact, for papers by Albert Hoenekopp Breakdown of academic impact, for papers by Athena Countouriotis Breakdown of academic impact, for papers by Franck E. Nicolini Breakdown of academic impact, for papers by Philippe Rousselot Breakdown of academic impact, for papers by P. Le Coutre Breakdown of academic impact, for papers by Franck E. Nicolini
Rankless by CCL
2026